FERMENTA · NSE
Fermenta Biotech Limited
₹474.15
+1.81% (+₹8.45)
Prev. close
₹465.7
Volume
26,096
Delivery %
58.1%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Fermenta Biotech Limited
Fermenta Biotech Limited, together with its subsidiaries, engages in the manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations, and environmental solution products in India, Europe, the United States, and internationally. It operates through Chemicals/Bulk Drug and Property segments. The company offers vitamin D3, including crystalline oil, resin oil, cold water dispersible, and feed grade powder for injectables, soft gel capsules, premixes, food and beverage fortification applications; and vitamin K1, vitamin E50, phenyramidol and silicon dioxide, and fish oil cholesterol. It also provides fortified rice kernel; and Fermase PS 250 and penicillin G acylase used in manufacturing processes of various antibiotics. In addition, the company offers design, engineering, procurement, and construction of wastewater treatment plants, STPs, and ETPs, as well as operation and maintenance services. Further, it is involved in property development business; and renting and selling of properties. The company was formerly known as DIL Limited. Fermenta Biotech Limited was incorporated in 1951 and is based in Thane, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Prashant Prabhakar Nagre
Headquarters
Thane
Employees
630
Website
fermentabiotech.comExchange
View on NSE ↗Key stats
Market cap
₹1,359.42 Cr
P/E ratio (TTM)
23.2
Dividend yield
0.81%
EPS (TTM)
₹20.40
Beta (5Y monthly)
-0.34
Shares float
77.44 L
EPS · quarter ended Jun 2026
₹3.34
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.3% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹377.29 Cr | ₹398.52 Cr | ₹349.06 Cr | ₹333.46 Cr | ₹467.09 Cr | ₹523.56 Cr | |
| EBITDA | — | — | ₹-4.07 Cr | ₹30.79 Cr | ₹120.62 Cr | ₹127.81 Cr |
| ₹42.53 Cr | ₹15.06 Cr | ₹-51.08 Cr | ₹-23.06 Cr | ₹76.86 Cr | ₹71.77 Cr | |
| Diluted EPS | ₹15.69 | ₹5.33 | ₹-17.7 | ₹-7.99 | ₹26.35 | ₹24.51 |
Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| — | — | — | ₹636.52 Cr | ₹547.83 Cr | ₹614.48 Cr | ₹647.94 Cr | |
| — | — | — | ₹219.52 Cr | ₹138.77 Cr | ₹114.94 Cr | ₹113.33 Cr | |
| Stockholders' equity | — | — | — | ₹315.31 Cr | ₹288.86 Cr | ₹362.67 Cr | ₹406.21 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹116.11 Cr | ₹105.35 Cr | ₹40.90 Cr | ₹92.83 Cr | |
| Investing cash flow | — | — | ₹-55.41 Cr | ₹-15.50 Cr | ₹-15.95 L | ₹-43.00 Cr |
| — | — | ₹-41.38 Cr | ₹-90.85 Cr | ₹-50.87 Cr | ₹-42.29 Cr | |
| Capital expenditure | — | — | ₹-40.49 Cr | ₹-19.21 Cr | ₹-22.13 Cr | ₹-30.33 Cr |
| End cash position | — | — | ₹17.75 Cr | ₹16.75 Cr | ₹6.63 Cr | ₹14.18 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Aug 26 |
|---|---|
| Promoter | 64.09% |
| Public | 33.36% |
| Employee trusts | 2.55% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Fermenta Biotech Limited | ₹1,347.52 Cr | ₹465.7 | 23.1 | 3.32 | 17.7% | 0.28 | +12.1% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.